Within its last year performance, AKBA rose by 24.53%, with highs and lows ranging from $2.48 to $0.78, whereas the simple moving average fell by -4.36% in the last 200 days.
On November 29, 2023, BTIG Research started tracking Akebia Therapeutics Inc. (NASDAQ: AKBA) recommending Buy. A report published by H.C. Wainwright on August 28, 2023, Upgraded its rating to ‘Buy’ for AKBA. Piper Sandler also Upgraded AKBA shares as ‘Overweight’, setting a target price of $4 on the company’s shares in a report dated May 31, 2023. Piper Sandler March 31, 2022d the rating to Neutral on March 31, 2022, and set its price target from $8 to $2. Needham March 31, 2022d its ‘Buy’ rating to ‘Hold’ for AKBA, as published in its report on March 31, 2022. Mizuho’s report from March 31, 2022 suggests a price prediction of $2 for AKBA shares, giving the stock a ‘Neutral’ rating. H.C. Wainwright also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Akebia Therapeutics Inc. (AKBA)
Further, the quarter-over-quarter decrease in sales is -22.58%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Akebia Therapeutics Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 0.82, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.92M can be a very valuable indicator of volatility for AKBA stock. On a monthly basis, the volatility of the stock is set at 4.55%, whereas on a weekly basis, it is put at 4.49%, with a gain of 3.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.50, showing growth from the present price of $1.32, which can serve as yet another indication of whether AKBA is worth investing in or should be passed over.
How Do You Analyze Akebia Therapeutics Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.03%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 24.18% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AKBA shares are owned by institutional investors to the tune of 24.18% at present.
